{"id":"W4392384788","doi":"10.1016/j.esmoop.2024.102388","title":"Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B)","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Aptitude Health; Oncolytics Biotech; Seagen; Puma Biotechnology; Daiichi-Sankyo; Genentech; Veracyte; Pfizer; Incyte; Queen Mary University of London; Clovis Oncology; Astellas Pharma; Eisai; Jazz Pharmaceuticals; National Institutes of Health; Natera; Baxalta; Amgen; Ariad Pharmaceuticals; National Cancer Institute; Servier; Gilead Sciences; Exelixis; Sanofi; GlaxoSmithKline; Celgene; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Les Laboratories Pierre Fabre","keywords":"Breast cancer; Medicine; Hazard ratio; Internal medicine; Oncology; Confidence interval; Proportional hazards model; Trastuzumab; Cohort; Regimen; Human Epidermal Growth Factor Receptor 2; Stage (stratigraphy); Clinical endpoint; Survival analysis; Cancer; Clinical trial","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009528996,0.0005537861,0.001026762,0.001261063,0.0005637154,0.0008572069,0.000664447,0.0005992256,0.002088217],"category_scores_gemma":[0.002508932,0.0003318498,0.000818615,0.002633419,0.000275718,0.0003010477,0.00139655,0.000467324,0.0007288289],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006094472,"about_ca_system_score_gemma":0.0009846325,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01302988,"about_ca_topic_score_gemma":0.01996131,"domain_scores_codex":[0.9993652,0.0001255377,0.00008158384,0.0002351328,0.0001090318,0.00008357862],"domain_scores_gemma":[0.9990181,0.0002585511,0.0002291831,0.0001763614,0.0001520773,0.0001657461],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002845257,0.000108746,0.9434961,0.0005317964,0.001895148,0.0005943377,0.0003085637,0.001713065,0.002576837,0.0002188595,0.03125071,0.01446059],"study_design_scores_gemma":[0.0003882907,0.0001356378,0.9819401,0.0001428594,0.0009117699,0.001296687,0.0003125102,0.001364756,0.0004980153,0.0002994675,0.01266713,0.00004270699],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8743747,0.001737407,0.000307189,0.000316335,0.0000275904,0.00004010967,0.1224202,0.00003617812,0.0007402297],"genre_scores_gemma":[0.6782414,0.001259958,0.0009937905,0.0002695107,0.00004303031,0.0002291941,0.3182717,0.0000514096,0.0006400741],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01302988,"threshold_uncertainty_score":0.02590805,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01337270380704992,"score_gpt":0.3078393079096106,"score_spread":0.2944666041025606,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}